Development of autoimmune pemphigus vulgaris following Chadox1 nCov-19 coronavirus vaccine (recombinant)
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20232059Keywords:
Pemphigus vulgaris, Autoimmune disease, CovishieldAbstract
Pemphigus vulgaris is a rare IgG-mediated autoimmune disease that affects the skin and mucous membranes, causing painful blistering. Pemphigus vulgaris has been reported to be triggered or exacerbated by various factors, including genetic vulnerability, certain drugs, and malignant diseases. We present a case of a patient who was admitted to the dermatology ward with complaints of multiple fluid-filled lesions, initially over the chest, containing clear fluid-filled, ruptured within 1 to 2 hours to leave behind painful raw areas, predominantly over the trunk, scalp, face, upper limbs in the past 2 weeks, and single raw erosions inside the oral cavity after receiving the second dose of Chadox1 nCov-19 coronavirus vaccine (Covishield™), and also mentioned he had developed similar symptoms after the 1st dose of COVID vaccine. We chose to report this case because of the unusual presentation of a rare COVID vaccine adverse drug reaction seen in India.
References
Kridin K, Schmidt E. Epidemiology of Pemphigus. JID Innov. 2021;1(1):100004.
Kanwar A, De D. Pemphigus in India. Indian J Dermatol Venereol Leprol. 2011;77(4):439.
Ishay Y, Kenig A, Tsemach-Toren T, Amer R, Rubin L, Hershkovitz Y, Kharouf F. Autoimmune phenomena following SARS-CoV-2 vaccination. Int Immunopharmacol. 2021;99:107970.
Sah R, Shrestha S, Mehta R, Sah SK, Rabaan AA, Dhama K, Rodriguez-Morales AJ. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal. Travel Med Infect Dis. 2021;40:101989.
Azzi L, Toia M, Stevanello N, Maggi F, Forlani G. An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine. Oral Dis. 2022;28:2583-5.
